CFO
NBIX icon

CVA Family Office’s Neurocrine Biosciences NBIX Stock Holding History

CVA Family Office’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4K Buy
103
+12
+13% +$1.78K ﹤0.01% 857
2026
Q1 		$12K Buy
+91
New +$12.1K ﹤0.01% 934

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CVA Family Office's NBIX Position: Q2 2026 in Review

CVA Family Office increased its Neurocrine Biosciences (NBIX) stake by 13% in Q2 2026, buying an estimated $1.78K and bringing the position to 103 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #857.

CVA Family Office first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CVA Family Office held 103 shares of Neurocrine Biosciences worth $17.4K as of Q2 2026.
  • CVA Family Office bought 12 Neurocrine Biosciences shares in Q2 2026, an estimated $1.78K.
  • Neurocrine Biosciences made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #857 holding.
  • CVA Family Office first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.